- Home
- HLVX vs ELUT Comparison
HLVX vs ELUT Comparison
Compare HLVX & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- ELUT
- Stock Information
- Founded
- HLVX 2020
- ELUT 2015
- Country
- HLVX United States
- ELUT United States
- Employees
- HLVX N/A
- ELUT N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- ELUT Medical Specialities
- Sector
- HLVX Health Care
- ELUT Health Care
- Exchange
- HLVX Nasdaq
- ELUT Nasdaq
- Market Cap
- HLVX 93.1M
- ELUT 108.2M
- IPO Year
- HLVX 2022
- ELUT 2020
- Fundamental
- Price
- HLVX $1.90
- ELUT $3.20
- Analyst Decision
- HLVX Hold
- ELUT Strong Buy
- Analyst Count
- HLVX 5
- ELUT 2
- Target Price
- HLVX $2.33
- ELUT $10.00
- AVG Volume (30 Days)
- HLVX 324.9K
- ELUT 46.3K
- Earning Date
- HLVX 11-07-2024
- ELUT 03-06-2025
- Dividend Yield
- HLVX N/A
- ELUT N/A
- EPS Growth
- HLVX N/A
- ELUT N/A
- EPS
- HLVX N/A
- ELUT N/A
- Revenue
- HLVX N/A
- ELUT $24,782,000.00
- Revenue This Year
- HLVX N/A
- ELUT $4.29
- Revenue Next Year
- HLVX N/A
- ELUT $32.21
- P/E Ratio
- HLVX N/A
- ELUT N/A
- Revenue Growth
- HLVX N/A
- ELUT N/A
- 52 Week Low
- HLVX $1.55
- ELUT $2.28
- 52 Week High
- HLVX $20.22
- ELUT $5.24
- Technical
- Relative Strength Index (RSI)
- HLVX 42.75
- ELUT 40.50
- Support Level
- HLVX $1.87
- ELUT $2.86
- Resistance Level
- HLVX $2.15
- ELUT $3.33
- Average True Range (ATR)
- HLVX 0.09
- ELUT 0.30
- MACD
- HLVX -0.02
- ELUT -0.05
- Stochastic Oscillator
- HLVX 21.87
- ELUT 24.64
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.